Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

Therapeutic Advances in Musculoskeletal Disease

Volumn 2, Issue 1, 2010, Pages 3-16

  Rizzoli, René ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

bone mineral density; glucocorticoid induced osteoporosis; hip fractures; osteopenia; osteoporosis; postmenopausal; zoledronic acid

Indexed keywords

EID: 84993812252     PISSN: 1759720X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1759720X09352920     Document Type: Review

References (49)

1. Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A. et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809-1822.
2. Black, D.M., Eastell, R., Cosman, F., Man, Z., Bucci-Rechtweg, C. and Mesenbrink, P. ( 2009) Effect of once-yearly zoledronic acid 5 mg on ‘super six’ non-vertebral fractures. Bone 44(Suppl 2): S429.
3. Boonen, S., Black, D., Sellmeyer, D., Eriksen, E.F., Bone, H. and Skag, A. ( 2008a) The skeletal response to zoledronic acid is not affected by renal impairment: results from the HORIZON-PFT study. Ann Rheum Dis 67(Suppl II): 402.
4. Boonen, S., Sellmeyer, D.E., Lippuner, K., Orlov-Morozov, A., Abrams, K., Mesenbrink, P. et al. (2008 b) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74: 641-648.
5. Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M. and Haentjens, P. ( 2008c) Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 264: 315-332.
6. Boonen, S., Black, D.M., Colón-Emeric, C., Delmas, P., Eastell, R., Magaziner, J. et al. (2009) Annual treatment with zoledronic acid continues to be effective in old age. Osteoporos Int 20(Suppl 1): S5-S22.
7. Brufsky, A.M. ( 2008) Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13: 187-195.
8. Cohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M. et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42: 2309-2318.
9. Colón-Emeric, C., Kuchibhatla, M., Pieper, C., Hawkes, W., Fredman, L., Magaziner, J. et al. (2003) The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 14: 879-883.
10. Conte, P. and Guarneri, V. ( 2004) Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9(Suppl 4): 28-37.
11. Cramer, J.A., Amonkar, M.M., Hebborn, A. and Altman, R. ( 2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21: 1453-1460.
12. de Nijs, R.N., Jacobs, J.W., Lems, W.F., Laan, R.F., Algra, A., Huisman, A.M. et al. (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355: 675-684.
13. Devogelaer, J.P., Brown, J.P., Burckhardt, P., Meunier, P.J., Goemaere, S., Lippuner, K. et al. (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18: 1211-1218.
14. Eastell, R., Black, D.M., Boonen, S., Adami, S., Felsenberg, D., Lippuner, K. et al. (2009) Effect of once-yearly zoledronic acid 5 mg on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 94: 3215-3225.
15. Eriksen, E.F., Lyles, K.W., Colón-Emeric, C.S., Pieper, C.F., Magaziner, J.S., Adachi, J.D. et al. (2009) Antifracture efficacy and reduction of mortality in relation to timing of first dose of zoledronic acid after hip fracture. J Bone Miner Res 24: 1308-1313.
16. European Medicines Agency. Assessment report for Aclasta, Type II variation. European Medicines Agency. EMEA/H/C/000595/II/0016. (2008) Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/aclasta/Aclasta-H-535-II-16-AR.pdf. Accessed 12 June 2009.
17. Gnant, M.F., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M. et al. (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25: 820-828.
18. Grbic, J.T., Landesberg, R., Lin, S.Q., Mesenbrink, P., Reid, I.R., Leung, P.C. et al. (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139: 32-40.
19. Huybrechts, K.F., Ishak, K.J. and Caro, J.J. ( 2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38: 922-928.
20. Jarrett, S.J., Conaghan, P.G., Sloan, V.S., Papanastasiou, P., Ortmann, C.E., O'Connor. et al. ( 2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54: 1410-1414.
21. Lippuner, K., Eastell, R., Reid, D.M., Bengtsson, C., Recknor, C. and Ish-Shalom, S. ( 2008) Effect of previous bisphosphonate use on response to zoledronic acid: results from the HORIZON-PFT study. Ann Rheum Dis 67(Suppl II): 57.
22. Lo, J.C., Pressman, A.R., Omar, M.A. and Ettinger, B. ( 2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17: 922-928.
23. Lyles, K.W., Colón-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C. et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1809.
24. Mazziotti, G., Giustina, A., Canalis, E. and Bilezikian, J.P. ( 2007) Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol 51: 1404-1412.
25. McClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A. et al. (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41: 122-128.
26. McClung, M.R., Miller, P., Recknor, C., Bucci-Rechtweg, C., Yu, S. and Benhamou, C.L. Efficacy and safety of zoledronic acid 5 mg in the prevention of osteoporosis in postmenopausal women with osteopenia: The HORIZON Prevention Study. (2009) Osteoporos Int 20(Suppl 2): S191-S229.
27. Michaelson, M.D., Kaufman, D.S., Lee, H., McGovern, F.J., Kantoff, P.W., Fallon, M.A. et al. (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25: 1038-1042.
28. Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P. and Ma, K.M. ( 2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 19: 357-364.
29. Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W. et al. (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617-627.
30. Novartis Europharm Limited. (2008) Aclasta summary of product characteristics Novartis Europharm Limited: Horsham, United Kingdom.
31. Pfeilschifter, J. and Diel, I.J. ( 2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18: 1570-1593.
32. Recker, R.R., Delmas, P.D., Halse, J., Reid, I.R., Boonen, S., Garcia-Hernandez, P.A. et al. (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23: 6-16.
33. Reid, D.M., Hughes, R.A., Laan, R.F., Sacco-Gibson, N.A., Wenderoth, D.H., Adami, S. et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15: 1006-1013.
34. Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U. et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653-661.
35. Reid, D.M., Delmas, P.D., Bone, H., Skag, A., Giannini, S., Lippuner, K. et al. (2008) Zoledronic acid reduces fractures and increases bone mineral density with and without concomitant osteoporosis therapy: results from the HORIZON-PFT study. Ann Rheum Dis 67(Suppl II): 635.
36. Reid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y. et al. (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253-1263.
37. Rizzoli, R., Burlet, N., Cahall, D., Delmas, P.D., Eriksen, E.F., Felsenberg, D. et al. (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841-847.
38. Robbins, J., Aragaki, A.K., Kooperberg, C., Watts, N., Wactawski-Wende, J., Jackson, R.D. et al. (2007) Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 298: 2389-2398.
39. Ryg, J., Rejnmark, L., Overgaard, S., Brixen, K. and Vestergaard, P. ( 2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res 24: 1299-1307.
40. Saag, K., Lindsay, R., Kriegman, A., Beamer, E. and Zhou, W. ( 2007a) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40: 1238-1243.
41. Saag, K.G., Shane, E., Boonen, S., Marin, F., Donley, D.W., Taylor, K.A. et al. (2007 b) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028-2039.
42. Silverman, S. ( 2006) Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am 32: 721-731.
43. Siris, E.S., Harris, S.T., Rosen, C.J., Barr, C.E., Arvesen, J.N., Abbott, T.A. et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81: 1013-1022.
44. Smith, M.R., Eastham, J., Gleason, D.M., Shasha, D., Tchekmedyian, S. and Zinner, N. ( 2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008-2012.
45. Suzuki, K., Takeyama, S., Sakai, Y., Yamada, S. and Shinoda, H. ( 2006) Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci 100: 189-194.
46. US Food and Drug Administration (FDA). (2008 ) Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates.
47. US Food and Drug Administration (FDA). (2009 ) Drug Safety Newsletter. Volume 2, Number 2. Available at: www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/default.htm. Accessed 31 July 2009.
48. Weiss, H.M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A. and Schran, H. ( 2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36: 2043-2049.
49. Yood, R.A., Emani, S., Reed, J.I., Lewis, B.E., Charpentier, M. and Lydick, E. ( 2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14: 965-968.